Abstract 2124
Background
To explore the differences of MRI scan between pituitary adenomas and craniopharyngioma from MR image features to 3D based texture features.
Methods
A total number of 131 patients were introduced into this study (pituitary Adenomas =68; craniopharyngioma=63) with pre-surgery MRI image. Qualitative MR features and MRI texture features of lesion were evaluated using chi-square tests, Fisher exact test or Mann-Whitney U test. Multivariate logistic regression analyses were performed to access their ability as independent predictors. Accuracy measures were calculated substantially for the significant features.
Results
Five MRI features were suggested to be significantly different between pituitary adenomas and craniopharyngioma and one of them, cystic alteration could be considered as independent practical predictors. Three texture features from contrast enhanced images (Histo-Skewness, GLCM-Contrast and GLCM-Energy), two texture features from T2WI (Histo-Skewness and GLCM-Contrast) were found to be significantly related to discrimination between two types of diseases. Two texture features (Histo-Skewness and GLCM-Contrast) were found significantly to be in relation with cystic alteration.
Conclusions
Both of MRI image features and texture features, could make significant discrimination between pituitary adenoma and craniopharyngioma and represent practical diagnostic value; in addition, two type features associate with each other.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuelei Ma.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract
4317 - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction
Presenter: Yixun Lu
Session: Poster Display session 2
Resources:
Abstract
4099 - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer
Presenter: Xinxin Wang
Session: Poster Display session 2
Resources:
Abstract
3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer
Presenter: Se Jun Park
Session: Poster Display session 2
Resources:
Abstract
1718 - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study
Presenter: Charlotte Stroes
Session: Poster Display session 2
Resources:
Abstract
5403 - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Presenter: Thierry Alcindor
Session: Poster Display session 2
Resources:
Abstract
591 - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.
Presenter: Kelly-Marie Crampton
Session: Poster Display session 2
Resources:
Abstract
1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
Presenter: Tsutomu Hayashi
Session: Poster Display session 2
Resources:
Abstract
3743 - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer
Presenter: Zimin Liu
Session: Poster Display session 2
Resources:
Abstract
2032 - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer
Presenter: Maria Svensson
Session: Poster Display session 2
Resources:
Abstract